CAS 87153-04-6: 6-[4-[(1S)-1-(4-hydroxycyclohexyl)tetrazol-5-yl]butoxy]-3,4-dihydro-1H-quinolin-2-one

Cilostazol is a drug that belongs to the class of antiplatelet agents and is prescribed for the prevention of thrombotic events. Cilostazol has been shown to inhibit platelet aggregation by blocking adenosine diphosphate (ADP) receptors on the platelets. It also inhibits p38, an enzyme involved in apoptosis. This drug has shown to be effective in reducing atherosclerosis and preventing cardiovascular disease, but carries the risk of adverse effects such as gastrointestinal bleeding. The drug is absorbed orally, but can be reconstituted with water if taken with food or milk. Cilostazol has been shown to have a pharmacokinetic profile similar to cilostamide, which is another anti-platelet agent.

Applications A metabolite of Cilostazol. References de Morais, S., et al.: J. Biol. Chem., 269, 15419 (1994), Tata, P; J Pharm Biomed Anal 2001, 24, 381 ,Hiratsuka, M; Eur J Clin Pharmacol 2002, 58, 417 ,,Roy, J; Drug Metab Dispos 2005, 33, 884

Applications 4’’-Hydroxy-cilostazol-d5 is a labelled metabolite of Cilostazol. References de Morais, S., et al.: J. Biol. Chem., 269, 15419 (1994), Tata, P; J Pharm Biomed Anal 2001, 24, 381,Hiratsuka, M; Eur J Clin Pharmacol 2002, 58, 417,,Roy, J; Drug Metab Dispos 2005, 33, 884